文献速递糖尿病

SGLT2抑制剂治疗与因COVID-19住院的2型糖尿病患者糖尿病酮症酸中毒及死亡率之间的关联

Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.
PubMed 文献 · Diabetes Care · 2022-09-08

这项回顾性队列研究基于英国40个中心全国审计数据(截至2020年12月),纳入3067例因COVID-19住院的2型糖尿病患者,其中230例(7.5%)入院前已处方SGLT2抑制剂。校正后SGLT2抑制剂使用与糖尿病酮症酸中毒风险无显著差异(OR 0.56;95%CI 0.16-1.97),与死亡率亦无显著关联(OR 1.13;95%CI 0.78-1.63)。

要点

  • 因COVID-19住院的2型糖尿病患者中,2.8%发生糖尿病酮症酸中毒,35.6%死亡。
  • 校正后SGLT2抑制剂使用与糖尿病酮症酸中毒风险无显著差异(OR 0.56;95%CI 0.16-1.97)。
  • SGLT2抑制剂使用与死亡率无显著关联(OR 1.13;95%CI 0.78-1.63)。

核心结论

  • 因COVID-19住院的2型糖尿病患者中糖尿病酮症酸中毒风险低而死亡率高,研究把握度有限,但未发现SGLT2抑制剂处方与糖尿病酮症酸中毒或住院死亡率风险增加相关的证据。

研究设计与样本

  • 回顾性队列研究,基于英国40个中心网络的大型全国审计数据的二次分析,数据收集截至2020年12月。
  • 原始全国审计纳入3067例因COVID-19住院的2型糖尿病患者,其中230例(7.5%)入院前已处方SGLT2抑制剂。
  • 采用粗模型、年龄-性别校正模型和多变量logistic回归模型,计算处方SGLT2抑制剂者与未处方者的比值比(OR)和95%CI。

主要发现

  • 总队列平均年龄72岁,62.3%为男性,34.9%使用胰岛素。
  • 总人群中2.8%发生糖尿病酮症酸中毒,35.6%死亡。
  • 校正后糖尿病酮症酸中毒的比值比在处方SGLT2抑制剂者与未处方者之间无显著差异(OR 0.56;95%CI 0.16-1.97)。
  • SGLT2抑制剂相关的校正后死亡比值比在总研究人群中相似(OR 1.13;95%CI 0.78-1.63)。
  • 在胰岛素亚组中SGLT2抑制剂相关的校正后死亡比值比为1.02(95%CI 0.59-1.77),在发生糖尿病酮症酸中毒亚组中为0.21(95%CI 0.01-8.76)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究把握度有限(原文述limited power)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the association between prescription of SGLT2 inhibitors (SGLT2is) and diabetic ketoacidosis (DKA) incidence or mortality in people with type 2 diabetes (T2D) hospitalized with COVID-19. RESEARCH DESIGN AND METHODS: This was a retrospective cohort study based on secondary analysis of data from a large nationwide audit from a network of 40 centers in the U.K. with data collection up to December 2020. The study was originally designed to describe risk factors associated with adverse outcomes among people with diabetes who were admitted to hospital with COVID-19. The primary outcome for this analysis was DKA on or during hospital admission. The secondary outcome was mortality. Crude, age-sex adjusted, and multivariable logistic regression models were used to generate odds ratios (ORs) and 95% CIs for people prescribed SGLT2i compared with those not prescribed SGLT2i. RESULTS: The original national audit included 3,067 people with T2D who were admitted to hospital with COVID-19, of whom 230 (7.5%) were prescribed SGLT2is prior to hospital admission. The mean age of the overall cohort was 72 years, 62.3% were men, and 34.9% were prescribed insulin. Overall, 2.8% of the total population had DKA and 35.6% of people in the study died. The adjusted odds of DKA were not significantly different between those prescribed SGLT2is and those not (OR 0.56; 95% CI 0.16-1.97). The adjusted odds of mortality associated with SGLT2is were similar in the total study population (OR 1.13; 95% CI 0.78-1.63), in the subgroup prescribed insulin (OR 1.02; 95% CI 0.59-1.77), and in the subgroup that developed DKA (OR 0.21; 95% CI 0.01-8.76). CONCLUSIONS: We demonstrate a low risk of DKA and high mortality rate in people with T2D admitted to hospital with COVID-19 and limited power, but no evidence, of increased risk of DKA or in-hospital mortality associated with prescription of SGLT2is.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Khunti K, Ruan Y, Davies J, et al. Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19. Diabetes Care. 2022. PMID: 36074663. doi:10.2337/dc22-0357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。